References
- Lynch, T.J.; Bell, D.W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R.A.; Brannigan, B.W.; Harris, P.L.; Haserlat, S.M.; Supko, J.G.; Haluska, F.G.; et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350, 2129–2139.
- Paez, J.G. EGFR Mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004, 304, 1497–1500.
- Mok, T.S.; Wu, Y.L.; Ahn, M.J.; Garassino, M.C.; Kim, H.R.; Ramalingam, S.S.; Shepherd, F.A.; He, Y.; Akamatsu, H.; Theelen, W.S.; et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N. Engl. J. Med. 2016,
- Lerch, M.; Mainetti, C.; Beretta-Piccoli, B.T.; Harr, T. Current perspectives on stevens-johnson syndrome and toxic epidermal necrolysis. Clin. Rev. Allergy Immunol. 2017, 54, 147–176.
- Lin, Y.T.; Chu, C. Osimertinib-induced Stevens-Johnson syndrome in a patient with EGFR T790M mutation-positive non-small cell lung cancer. Lung Cancer 2019, 129, 110–111.
- Ko TM, et al. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome. J Allergy Clin Immunol. 2011;128(6):1266–76.
- De Araujo E, et al. Death ligand TRAIL, secreted by CD1a + and CD14 + cells in blister fluids, is involved in killing keratinocytes in toxic epidermal necrolysis. Exp Dermatol. 2011; 20(2): 107–12.
- Mok TS, Wu YL, Ahn MJ et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 2017; 376: 629–640.
- Ohe, Y.; Imamura, F.; Nogami, N.; Okamoto, I.; Kurata, T.; Kato, T.; Sugawara, S.; Ramalingam, S.S.; Uchida, H.; Hodge,R.; etal. Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset. Jpn. J. Clin. Oncol. 2019, 49, 29–36.
- Yang JC, Ahn MJ, Kim DW et al. Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension compo nent. J Clin Oncol 2017; 35: 1288–1296.
- Goss G,Tsai CM, Shepherd FA et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): A multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 2016; 17: 1643–1652.
- Soria JC, Ohe Y,Vansteenkiste J et al. Osimertinib in untreated EGFR-mutated advanced non small-cell lung cancer. N Engl J Med 2017; 378: 113–125.
- Kozuki, T. Skin problems and EGFR-tyrosine kinase inhibitor. Jpn. J. Clin. Oncol. 2016, 46, 291–298.
- Chung,W.H.; Hung, S.I.; Hong, H.S.; Hsih, M.S.; Yang, L.C.; Ho, H.C.; Wu, J.Y.; Chen, Y.T. Medical genetics: Amarker for Stevens-Johnson syndrome. Nature 2004, 428, 486.
- Khoo, A.; Foo, C. Toxic epidermal necrolysis in a burns centre: A 6-year review. Burns 1996, 22, 275–278.
- Roujeau, J.C.; Kelly, J.P.; Naldi, L.; Rzany, B.; Stern, R.S.; Anderson, T.; Auquier, A.; Bastuji-Garin, S.; Correia, O.; Locati, F.; et al. Medication use and the risk of stevens–johnson syndrome or toxic epidermal necrolysis. N. Engl. J. Med. 1995, 333, 1600–1608.
- Lonjou, C.; Thomas, L.; Borot, N.; Ledger, N.; De Toma, C.; LeLouet, H.; Graf, E.; Schumacher, M.; Hovnanian, A.; Mockenhaupt,M.; etal. AmarkerforStevens-Johnsonsyndrome: Ethnicitymatters. Pharm. J. 2006, 6, 265–268.
- Wang, J.; Cheng, X.; Lu, Y.; Zhou, B. A case report of toxic epidermal necrolysis associated with AZD-9291. Drug Des. Dev. Ther. 2018, 12, 2163–2167.
- Huang, J.J.; Ma, S.-X.; Hou, X.; Wang, Z.; Zeng, Y.D.; Qin, T.; Dinglin, X.X.; Chen, L.K. Toxic epidermal necrolysis related to AP (pemetrexed plus cisplatin) and gefitinib combination therapy in a patient with metastatic non-small cell lung cancer. Chin. J. Cancer 2015, 34, 94–98
- Doesch, J.; Debus, D.; Meyer, C.; Papadopoulos, T.; Schultz, E.S.; Ficker, J.H.; Brueckl, W. Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient. Lung Cancer 2016 95, 35–38.
- Otsuka,T; Tanaka,A.;Azukizawa,H.; Sasaki,S.; Ishijima,M.; Matsuki,T.; Osa,A.; Nakatani,T.; Kuroyama,M.; Hirata, H.; et al. Successful treatment with gefitinib after Stevens–Johnson syndrome associated with afatinib therapy in apatient with adenocarcinoma of the lung. Int. Cancer Conf. J. 2016, 6, 38–41
- Rittberg R, Ho C, Wang Y. Acute Onset of a Life-Threatening Skin Toxicity Due to Osimertinib: Severe Psoriasis Versus Toxic Epidermal Necrolysis Cureus. 2022 Apr 26; 14(4): e24513.
- Yunhua Xu,, Yong Li, Jie Luo and Rong Tang Osimertinib-induced Keratitis and Secondary Toxic Epidermal Necrotic Drug Eruption- A Case Report and Literature Review Current Drug Safety, 2024, 19, 309–312.